SORCS1 and synucleinopathy: Thus, in future studies, it will be important to address whether and how SorCS1 overexpression and anti-NRX1β treatment rescue α-syn PFF-induced pathology in culture and in vivo for the development of novel therapeutic strategies for synucleinopathies.